A curated database of genetic markers from the angiogenesis/VEGF pathway and their relation to clinical outcome in human cancers

Acta Oncologica

Volumn 51, Issue 2, 2012, Pages 243-246

  Savas, Sevtap ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; DATA BASE; DNA POLYMORPHISM; GENE MUTATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

DATABASES, GENETIC; GENETIC MARKERS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84856488426     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.636758     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. World Health Organization (WHO). The global burden of disease: 2004 update. Geneva: WHO: 2008.
3. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-10.
4. Savas S, Liu G. Genetic variations as cancer prognostic markers: Review and update. Hum Mutat 2009;30: 1369-77.
5. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
6. Cao Y. Tumor angiogenesis and molecular targets for therapy. Front Biosci 2009;14:3962-73.
7. Bhat TA, Singh RP. Tumor angiogenesis - a potential target in cancer chemoprevention. Food Chem Toxicol 2008;46: 1334-45.
8. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008;130:1091-103.
9. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: The evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003;169:1122-33.
10. Onn A, Fidler IJ. Metastatic potential of human neoplasms. In Vivo 2002;16:423-9.
11. Robinson VL, Kauffman EC, Sokoloff MH, Rinker-Schaeffer CW. The basic biology of metastasis. Cancer Treat Res 2004; 118:1-21.
12. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: Changing views. J Pathol 2008;214:283-93.
13. Stacker SA, Achen MG. From anti-angiogenesis to antilymphangiogenesis: Emerging trends in cancer therapy. Lymphat Res Biol 2008;6:165-72.
14. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ. The lethal phenotype of cancer: The molecular basis of death due to malignancy. CA Cancer J Clin 2007; 57:225-41.
15. I iizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy. Biochim Biophys Acta 2008; 1786:87-104.
16. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-41.
17. MacGabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 2008;15: 715-38.
18. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
19. Anargyrou K, Dimopoulos MA, Sezer O, Terpos E. Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 2008;49:677-89.
20. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008;28:23S - 30.
21. Kelly K, Huang C. Biological agents in non-small cell lung cancer: A review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol 2008;3:664-73.
22. Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: Antiangiogenic therapies for gastrointestinal cancers - focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol 2008;5:250-67.
23. Srinivasan R, Armstrong AJ, Dahut W, George DJ. Antiangiogenic therapy in renal cell cancer. BJU Int 2007;99: 1296-300.
24. Gridelli C, Rossi A, Maione P. New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 2006;60:76-86.
25. Savas S, Younghusband HB. dbCPCO: A database of genetic markers tested for their predictive and prognostic value in colorectal cancer. Hum Mutat 2010;31:901-7.
26. Blansfi eld JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007;142:814 - 8; discussion 818.e1-2.
27. Ohshima J, Haruta M, Arai Y, Kasai F, Fujiwara Y, Ariga T, et al. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identifi ed in a 7p21 homozygous deletion region in a Wilms tumor. Genes Chromosomes Cancer 2009;48: 1037-50.
28. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II Consortium study. J Clin Oncol 2010;28:3491-7.
29. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defi nes VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004;46:293-8.
30. Yamamori M, Sakaeda T, Nakamura T, Okamura N, Tamura T, Aoyama N, et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 2004;325:144-50.
31. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468-71.
32. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identifi cation of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000;12:1232-5